BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35927957)

  • 1. Effects of clot contraction on clot degradation: A mathematical and experimental approach.
    Risman RA; Abdelhamid A; Weisel JW; Bannish BE; Tutwiler V
    Biophys J; 2022 Sep; 121(17):3271-3285. PubMed ID: 35927957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood clot contraction differentially modulates internal and external fibrinolysis.
    Tutwiler V; Peshkova AD; Le Minh G; Zaitsev S; Litvinov RI; Cines DB; Weisel JW
    J Thromb Haemost; 2019 Feb; 17(2):361-370. PubMed ID: 30582674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling fibrinolysis: a 3D stochastic multiscale model.
    Bannish BE; Keener JP; Fogelson AL
    Math Med Biol; 2014 Mar; 31(1):17-44. PubMed ID: 23220403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction.
    Kunitada S; FitzGerald GA; Fitzgerald DJ
    Blood; 1992 Mar; 79(6):1420-7. PubMed ID: 1547340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis.
    Jones AJ; Meunier AM
    Thromb Haemost; 1990 Nov; 64(3):455-63. PubMed ID: 2128976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling fibrinolysis: 1D continuum models.
    Bannish BE; Keener JP; Woodbury M; Weisel JW; Fogelson AL
    Math Med Biol; 2014 Mar; 31(1):45-64. PubMed ID: 23220467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy.
    Sakharov DV; Nagelkerke JF; Rijken DC
    J Biol Chem; 1996 Jan; 271(4):2133-8. PubMed ID: 8567670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered plasma fibrin clot properties in essential thrombocythemia.
    MaƂecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
    Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
    Gurewich V; Pannell R
    Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat.
    Reilly CF; Fujita T; Mayer EJ; Siegfried ME
    Arterioscler Thromb; 1991; 11(5):1276-86. PubMed ID: 1911713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and biophysical conditions for blood clot lysis.
    Sabovic M; Blinc A
    Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
    Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous fibrinolysis facilitates clot retraction in vivo.
    Samson AL; Alwis I; Maclean JAA; Priyananda P; Hawkett B; Schoenwaelder SM; Jackson SP
    Blood; 2017 Dec; 130(23):2453-2462. PubMed ID: 29074499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clot lysis induced by a monoclonal antibody against alpha 2-plasmin inhibitor.
    Sakata Y; Eguchi Y; Mimuro J; Matsuda M; Sumi Y
    Blood; 1989 Dec; 74(8):2692-7. PubMed ID: 2510836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinolysis: an illustrated review.
    Risman RA; Kirby NC; Bannish BE; Hudson NE; Tutwiler V
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100081. PubMed ID: 36942151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clot retraction facilitates clot lysis.
    Carroll RC; Gerrard JM; Gilliam JM
    Blood; 1981 Jan; 57(1):44-8. PubMed ID: 7448414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate.
    Weisel JW; Litvinov RI
    Cardiovasc Hematol Agents Med Chem; 2008 Jul; 6(3):161-80. PubMed ID: 18673231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.